Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

BiolineRx Jumps Most on Record After Deal With Genoscience

Jan. 24 (Bloomberg) -- BioLineRx Ltd. surged the most on record after the Israeli company that develops therapeutic pharmaceutical drugs signed a deal with France’s Genoscience to develop and commercialize a treatment.

The shares surged 37 percent, the most since February 2007 when Bloomberg started tracking them, to 1.645 shekels at the 4:30 p.m. close in Tel Aviv.

BioLineRx signed an “exclusive license agreement” with Genoscience for its BL-8020 oral treatment for Hepatitis C, it said in a filing with the Tel Aviv Stock Exchange.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.